Eton Pharmaceuticals, Inc. (ETON) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $28.00K; Additional Paid in Capital, Common StockUSD $145.92M; Additional Paid in CapitalUSD (m); Retained Earnings (Accumulated Deficit)USD $-99.36M.
- 2026-03-31: Common Stock, Value, IssuedUSD $27.00K; Additional Paid in Capital, Common StockUSD $141.53M; Additional Paid in CapitalUSD (m); Retained Earnings (Accumulated Deficit)USD $-110.94M.
- 2025-12-31: Common Stock, Value, IssuedUSD $27.00K; Additional Paid in Capital, Common StockUSD $138.62M; Additional Paid in CapitalUSD (m); Retained Earnings (Accumulated Deficit)USD $-112.49M.
- 2025-09-30: Common Stock, Value, IssuedUSD $27.00K; Additional Paid in Capital, Common StockUSD (m); Additional Paid in CapitalUSD $137.08M; Retained Earnings (Accumulated Deficit)USD $-113.98M.
Eton Pharmaceuticals, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Additional Paid in Capital USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $28.00K | $145.92M | (m) | $-99.36M | $46.59M | 3 month · $1.47M 6 month · $2.99M | (m) |
| 2026-03-31 | $27.00K | $141.53M | (m) | $-110.94M | $30.61M | 3 month · $1.52M | (m) |
| 2025-12-31 | $27.00K | $138.62M | (m) | $-112.49M | $26.15M | 12 month · $5.51M | (m) |
| 2025-09-30 | $27.00K | (m) | $137.08M | $-113.98M | $23.13M | 3 month · $1.09M 9 month · $4.39M | (m) |
| 2025-06-30 | $27.00K | (m) | $135.98M | $-112.05M | $23.96M | 3 month · $2.10M 6 month · $3.30M | (m) |
| 2025-03-31 | $27.00K | $133.89M | (m) | $-109.47M | $24.45M | 3 month · $1.20M | (m) |
| 2024-12-31 | $27.00K | $132.29M | $132.29M | $-107.89M | $24.43M | 12 month · $3.17M | 12 month · $1.17M |
| 2024-09-30 | $26.00K | $123.25M | (m) | $-107.30M | $15.98M | 3 month · $722.00K 9 month · $2.38M | 3 month · $1.17M 9 month · $1.17M |
| 2024-06-30 | $26.00K | $121.36M | (m) | $-107.92M | $13.46M | 3 month · $840.00K 6 month · $1.66M | (m) |
| 2024-03-31 | $26.00K | $120.35M | (m) | $-104.88M | $15.49M | 3 month · $821.00K | (m) |
| 2023-12-31 | $26.00K | $119.52M | (m) | $-104.07M | $15.48M | 12 month · $3.14M | (m) |
| 2023-09-30 | $26.00K | $118.68M | (m) | $-101.81M | $16.89M | 3 month · $730.00K 9 month · $2.39M | (m) |
| 2023-06-30 | $26.00K | $117.93M | (m) | $-101.23M | $16.73M | 3 month · $785.00K 6 month · $1.66M | (m) |
| 2023-03-31 | $26.00K | $117.01M | (m) | $-105.79M | $11.24M | 3 month · $872.00K | (m) |
| 2022-12-31 | $25.00K | $116.19M | (m) | $-103.13M | $13.08M | 12 month · $4.22M 24 month · $4.22M | (m) |
| 2022-09-30 | $25.00K | $115.20M | (m) | $-104.05M | $11.18M | 3 month · $949.00K 9 month · $3.09M | 9 month · $244.00K |
| 2022-06-30 | $25.00K | $114.22M | (m) | $-101.00M | $13.24M | 3 month · $1.06M 6 month · $2.14M | 3 month · $244.00K 6 month · $244.00K |
| 2022-03-31 | $25.00K | $112.80M | (m) | $-99.44M | $13.38M | 3 month · $1.08M | (m) |
| 2021-12-31 | $25.00K | $111.72M | (m) | $-94.11M | $17.63M | 12 month · $3.38M | (m) |
| 2021-09-30 | $25.00K | $110.79M | (m) | $-95.15M | $15.66M | 3 month · $1.01M 9 month · $2.52M | (m) |
| 2021-06-30 | $25.00K | $109.77M | (m) | $-89.06M | $20.74M | 3 month · $836.00K 6 month · $1.51M | (m) |
| 2021-03-31 | $24.00K | $108.57M | (m) | $-87.04M | $21.55M | 3 month · $673.00K | (m) |
| 2020-12-31 | $24.00K | $107.80M | (m) | $-92.16M | $17.63M | 12 month · $2.58M | (m) |
| 2020-09-30 | $21.00K | $85.84M | (m) | $-84.47M | $1.39M | (m) | (m) |
| 2020-06-30 | $21.00K | $84.98M | (m) | $-77.97M | $7.03M | (m) | (m) |
| 2020-03-31 | $21.00K | $83.84M | (m) | $-73.24M | $10.62M | (m) | (m) |
| 2019-12-31 | $18.00K | $74.72M | $74.72M | $-64.19M | $10.55M | (m) | (m) |
| 2019-09-30 | $18.00K | (m) | $73.82M | $-61.49M | $12.35M | (m) | (m) |
| 2019-06-30 | $18.00K | (m) | $73.21M | $-56.53M | $16.70M | (m) | (m) |
| 2019-03-31 | $18.00K | (m) | $72.50M | $-53.28M | $19.24M | (m) | (m) |
| 2018-12-31 | $18.00K | (m) | $72.15M | $-45.87M | $26.30M | (m) | 12 month · $3.10M |
| 2018-09-30 | $6.00K | (m) | $3.39M | $-19.81M | $-16.41M | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | $-12.94M | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | $-9.55M | (m) | (m) |
| 2017-12-31 | $6.00K | (m) | $1.76M | $-8.64M | $-6.87M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |